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Background: Direct cell-cell spread of HIV-1 is a very efficient mode of viral dissemination, with increasing evidence
suggesting that it may pose a considerable challenge to controlling viral replication in vivo. Much current vaccine
research involves the study of broadly neutralising antibodies (bNabs) that arise during natural infection with the
aims of eliciting such antibodies by vaccination or incorporating them into novel therapeutics. However, whether
cell-cell spread of HIV-1 can be effectively targeted by bNabs remains unclear, and there is much interest in
identifying antibodies capable of efficiently neutralising virus transmitted by cell-cell contact.
Results: In this study we have tested a panel of bNAbs for inhibition of cell-cell spread, including some not previously
evaluated for inhibition of this mode of HIV-1 transmission. We found that three CD4 binding site antibodies, one from
an immunised llama (J3) and two isolated from HIV-1-positive patients (VRC01 and HJ16) neutralised cell-cell
spread between T cells, while antibodies specific for glycan moieties (2G12, PG9, PG16) and the MPER (2F5) displayed
variable efficacy. Notably, while J3 displayed a high level of potency during cell-cell spread we found that the small size
of the llama heavy chain-only variable region (VHH) J3 is not required for efficient neutralisation since recombinant J3
containing a full-length human heavy chain Fc domain was significantly more potent. J3 and J3-Fc also neutralised
cell-cell spread of HIV-1 from primary macrophages to CD4+ T cells.
Conclusions: In conclusion, while bNabs display variable efficacy at preventing cell-cell spread of HIV-1, we find
that some CD4 binding site antibodies can inhibit this mode of HIV-1 dissemination and identify the recently described
llama antibody J3 as a particularly potent inhibitor. Effective neutralisation of cell-cell spread between physiologically
relevant cell types by J3 and J3-Fc supports the development of VHH J3 nanobodies for therapeutic or prophylactic
applications.
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All currently licensed vaccines against human viruses in-
duce humoral immunity and elicit antibodies that neutral-
ise the virus, thereby preventing infection of host cells
[1,2]. To date antibodies which broadly neutralise the
many diverse strains of Human Immunodeficiency Virus
Type-1 (HIV-1) have only been elicited during natural in-
fection or in the heavy-chain only antibody (HCAb) for-
mat found in llamas [3]. Consequently, much HIV-1
vaccine research involves the study of broadly neutralising
antibodies (bNabs) that arise in certain patients with the* Correspondence: c.jolly@ucl.ac.uk
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unless otherwise stated.goal of re-eliciting such antibodies by vaccination. This
work has primarily focused on the ability of such anti-
bodies to prevent infection of target cells by cell-free vi-
rions, notably in the standardised TZM-bl assay [4], which
has been instrumental in allowing comparison of anti-
bodies isolated from different patients and at various
stages of disease. However, infection of susceptible target
cells is also achieved via cell-cell contact. The predomin-
ant mode of cell-cell spread of HIV-1 is across virus-
induced immune cell contacts termed virological synapses
[5] that constitute >90% of cell-cell transmission events
in vitro [6], although longer range cell-cell transmission
via filopodia [7] and membrane nanotubes have also been
reported [8]. Notably, cell-cell spread of HIV-1 is signifi-
cantly more efficient than equivalent cell-free infectionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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spread attributed to a combination of factors including
polarised budding of the virus towards the target cell,
receptor clustering on the target cell enriching for viral
entry receptors, and the close physical contact between
cells limiting the requirement for prolonged virus diffu-
sion [5,10,14,15].
While the relative importance of these two mechanisms
of infection is difficult to definitively determine, there is
growing awareness that assessing only cell-free virus does
not adequately reflect the viral challenge present during
in vivo infection, particularly since lymphoid tissues which
are densely-packed with CD4+ T lymphocytes and thus
provide an ideal environment for efficient viral dissemin-
ation mediated by physical intercellular contacts. In
addition to increasing infection kinetics, it has been ar-
gued that the higher concentration of virus that can be
passed from an infected cell to an uninfected target cell is
of such a magnitude that some anti-retroviral agents are
not fully efficient at controlling in vivo infection despite
strong in vitro potency [16,17]. Furthermore cell-cell
spread of HIV-1 has also been suggested to be a means by
which HIV-1 may evade neutralising antibodies, and it has
been reported that antibodies targeting the CD4 binding
site are less able to neutralise infection by cell-cell spread
than antibodies targeting other sites on HIV-1 [18].
Multiple sites on the HIV-1 envelope protein (Env)
are targeted by bNabs, however many antibodies target
the conserved CD4 binding site on Env which the virus
uses to bind CD4 and infect host cells (e.g. HJ16,
VRC01, NIH45-46, PGV04, b12, J3) [3]. Thus, the CD4
binding site is a target of many vaccine strategies that
aim to induce bNabs at a protective level in the vacci-
nee at the time of exposure [19]. That anti-CD4 binding
site antibodies can be protective has been demonstrated
by the passive transfer of b12 to non-human primates
and resistance to subsequent viral challenge [20,21].
However, there are differences in the ability of anti-
CD4 binding site antibodies to neutralise HIV-1 both in
terms of breadth and potency, reflecting their matur-
ation in different hosts in response to diverse stimuli
and specific isolation methods. Recent advances in iso-
lating and eliciting of bNAbs against HIV-1 has led to
the identification of a number of new broad and potent
antibodies targeting the CD4 binding site including
VRC01, HJ16 and J3 [22-24]. J3 is particularly interest-
ing because unlike other broad and potent antibodies
that were isolated from HIV-1 infected individuals, J3 is
a HCAb variable region (VHH) that was isolated from a
llama immunised with recombinant gp140 from sub-
types A and B/C [22]. Llamas and other camelids con-
tain HCAbs of approximately 82 KDa in addition to
conventional antibodies of approximately 145 KDa [25].
In the HCAb all antigen-binding function is encoded inthe VHH, and as these small domains are both highly
stable and soluble these mini-antibodies have potential as
microbicides [26] and as molecular tools [27]. In addition,
they allow us to examine the relative importance of anti-
body size for effective neutralisation during cell-cell
spread by reconstituting the full-length HCAb parent anti-
body of J3.
In this study we have directly compared the relative effi-
cacy of antibodies targeting different epitopes within HIV-
1 Env for their ability to block cell-cell spread of HIV-1
between CD4+ T lymphocytes using a panel of antibodies
including some not previously tested for inhibition of cell-
cell spread (J3, HJ16 and PG9). We report that broad and
potent neutralising anti-CD4 binding site antibodies can
neutralise cell-cell transmission of HIV-1 while antibodies
2F5, 4E10, 2G12 and PG9/16 which target the membrane
proximal region (MPER), a high mannose patch and the
V1/V2 loop respectively [28-30] display variable efficacy.
In particular we found that J3 potently blocked cell-cell
spread between physiologically relevant cell types in-
cluding HIV-1 infected and uninfected T cells as well as
transmission from macrophages to T cells. Notably the
full-length heavy chain reconstituted VHH (J3-Fc) more
effectively neutralises HIV-1 infection mediated either
by cell-free or cell-cell spread, demonstrating that its
potency is not solely a function of the small size of the
antigen-binding VHH.
Results
T cell-T cell spread of HIV-1 is sensitive to antibody-
mediated inhibition
We compared a group of bNabs targeting different epi-
topes on HIV-1 Env for their ability to inhibit cell-cell
spread of HIV-1 between T cells. Notably, we evaluated in-
hibition of cell-cell spread by the recently described J3
VHH. J3 is a potent and broad inhibitor of cell-free HIV-1
infection [22] that is currently being evaluated as a poten-
tial microbicide in macaque challenge studies; however,
whether J3 displays similar potency during cell-cell spread
of HIV-1 has not been tested. To directly compare differ-
ent antibodies, Jurkat T cells were infected with HIV-1 by
spinoculation to achieve a synchronised population of in-
fected cells 48 h post infection. For inhibition assays, in-
fected Jurkat cells were incubated with serial dilutions of
each antibody for 1 h at 37°C, and then mixed with unin-
fected target Jurkat cells that contain an HIV-1 tat-
inducible luciferase gene (Jurkat 1G5). Luciferase reporter
gene expression was measured after 24 h, thereby allowing
direct quantification of new HIV-1 infection. This is a
time frame in which the faster infection kinetics of cell-
cell spread means this mode of viral spread dominates,
with little or no contribution from cell-free virus
[9,10,13,14,31] (Figure 1A) or syncytia formation [32].
Figure 1B shows that all four anti-CD4 binding site
Figure 1 Inhibition of HIV-1 T cell-T cell spread by anti-CD4 binding site, MPER and glycan-specific antibodies. (A) Quantification of the
luciferase signal in Jurkat 1G5 cells contributed by cell-cell and cell-free spread as described in the methods. Data show the mean and SEM
from 3 independent experiments. (B) Antibodies targeting the CD4 binding site, (C) the gp41 MPER and gp120 glycans and non neutralising
antibody controls (B6 and Lab5), were serially diluted and incubated with HIV-1 (NL4.3) infected Jurkat T cells for 1 h at 37°C. Uninfected target
T cells containing a luciferase-reporter gene were added and cells incubated for 24 h as described in the methods to allow for cell-cell spread of HIV-1.
Data are shown as the percentage neutralisation normalised to virus-only controls and representative of three independent experiments. (D) The average
IC50 values (μg/ml) were generated from duplicate titrations of the indicated antibodies in three independent experiments and show the mean with
the SEM.
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fection of T cells by cell-cell spread when compared to
a non-neutralising human antibody control (B6 [33]) or
the VHH negative control Lab5 [34]. Determination of
the 50% inhibitory concentration (IC50) (Figure 1D) re-
vealed that J3 was the most potent inhibitor of cell-cell
spread (IC50 = 2 μg/ml) followed by HJ16 (IC50 =
2.3 μg/ml) and VRC01 (IC50 = 7.8 μg/ml). Notably, b12
was less potent compared to the other antibodies
against this mode of transmission (IC50 = 16.1 μg/ml).
In addition three glycan-dependent and two anti-gp41
MPER antibodies were also assessed for inhibition of
cell-cell spread across the same concentration range
(Figure 1C and 1D). 2G12 was the first anti-glycan HIV-
1 neutralising antibody described [35,36] and binds a
high mannose cluster on gp120 through an unusualdomain-exchanged structure [37]. Figure 1C shows that
2G12 also inhibited cell-cell spread of HIV-1, albeit with
a higher IC50 than CD4 binding site bNabs J3, HJ16 and
VRC01 (Figure 1D). PG9 and PG16 neutralise up to 80%
of strains tested [28] via a glycan-dependent V1/V2 epi-
tope [38] and we found that these bNabs also prevented
cell-cell transmission but required a higher concentra-
tion (IC50 = 29 μg/ml and 13.1 μg/ml for PG9 and PG16
respectively) to achieve equivalent inhibition when com-
pared to J3 or HJ16, with PG16 exhibiting greater
potency than PG9 (Figure 1C and D). Finally two MPER-
specific HIV-1 neutralising antibodies were also tested.
Of these, only 2F5 was able to prevent cell-cell infec-
tion. 4E10 which has been reported to be less effective
at blocking cell-free infection when compared to 2F5 [39],
showed no inhibition of cell-cell spread (Figure 1C and D)
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IC50 in excess of >50 μg/ml.
We next used a different assay system that employs
quantitative real-time PCR (qPCR) to measure cell-cell
spread by enumerating the appearance of de novo HIV-1
DNA pol copies arising from reverse transcription within
the newly infected T cell population. The details and valid-
ation of this assay have been described elsewhere [9,10].
HIV-1 infected T cells were pre-incubated with bNabs at
10 μg/ml or 100 μg/ml for 1 h at 37°C, mixed with unin-
fected target cells and incubated for various periods of
time, after which the DNA was extracted and qPCR per-
formed. As expected, we observed a time-dependent in-
crease in the appearance of HIV-1 pol DNA indicative of
cell-cell spread within the control sample (UT) that was
incubated in the absence of antibody (Figure 2). Notably,
no statistically significant increase in the HIV-1 pol copy
number was seen in the presence of the CD4 binding site
bNabs J3, b12, VRC01 or HJ16 when used at either 10 μg/
ml or 100 μg/ml, indicative of impaired cell-cell spread of
HIV-1 in the presence of these antibodies (p <0.001). 4E10
again showed inefficient inhibition of cell-cell spread at
10 μg/ml when compared to other antibodies tested, and
gained statistically significant inhibitory activity only when
used at a 10-fold higher concentration.
Commonly used assays to evaluate neutralising activity of
antibodies raised against HIV-1 are performed by titratingFigure 2 Inhibition of cell-cell spread assayed by quantitative real-tim
(control) or incubated with 10 or 100 μg/ml of the indicated antibodies f
cells. DNA was extracted at 0, 3, 6 and 12 h and quantitative real-time PC
from de novo reverse transcription in newly-infected target cells. Data we
the fold increase in HIV-1 DNA copy number over time relative to the ba
HIV-1 DNA. Data are the mean with SD from a representative of 2 indepe
with Tukey’s post-test to compare each antibody to the control (untreate
for J3, b12 VRC01, and HJ16 were significantly different from untreated co
4E10 was significantly different from untreated controls at 6 h and 12 h ocell-free virus on HeLa TZM-bl reporter cells. Therefore,
we compared the relative inhibitory activity of our panel of
CD4-binding site antibodies during cell-free infection using
the standardised TZM-bl assay. Table 1 shows that all anti-
bodies targeting the CD4 binding site (J3, b12, VRC01 and
HJ16) inhibited cell-free virus infection with IC50 values
below 1 μg/ml, with J3 exhibiting approximately 10-fold
higher potency than b12. This is similar to cell-cell spread
(Figure 1) in which b12 was found to be 2–8 fold less ef-
fective than J3 and also other antibodies targeting the CD4
binding site (i.e. VRC01 and HJ16). Antibodies targeting
other epitopes of Env (MPER, V1/V2 and glycans) generally
showed reduced efficacy. Taken together these data show J3
to be an effective inhibitor of both modes of HIV-1
dissemination.
Neutralisation of cell-cell spread mediated by HIV-1-
infected primary T cells
While Jurkat T cells provide a reliable model in which to
evaluate inhibition, we wished to confirm our data using
primary CD4+ T cells, which are the main cell type in-
fected by HIV-1 during natural infection. To this end
CD4+ T cells were isolated from peripheral blood
mononuclear cells, stimulated with PHA and IL-2 and
infected with HIV-1 by spinoculation. After 48 h, HIV-1
infected primary CD4+ T cells were incubated with serial
dilutions of antibodies and mixed with Jurkat 1G5 targete PCR. HIV-1 (NL4.3) infected Jurkat cells were either left untreated
or 1 h at 37°C prior to mixing with uninfected Jurkat 1G5 target T
R was performed to measure the appearance HIV-1 pol DNA resulting
re normalised to the albumin housekeeping gene and expressed as
seline value at t = 0 h. Value of greater than 1 indicates an increase in
ndent experiments. Statistical analysis was performed using by Anova
d) at corresponding time points (t = 3 h, t = 6 h and t = 12 h). Values
ntrols at 6 h and 12 h at both antibody concentrations (p < 0.001).
nly when used at 100 μg/ml (p < 0.001).
Table 1 IC50 valuesa for inhibition of cell-free infection by bNabs
J3 HJ16 VRC01 b12 2F5 4E10 2G12 PG9 PG16
Cell-free 0.035 0.25 0.26 0.32 1.2 3.1 2.2 2.18 0.45
SEM 0.005 0.02 0.09 0.035 0.5 1.0 0.8 1.02 0.36
aIC50 values are μg/ml and were determined from at least three independent experiments as described in the Methods.
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exactly as described in Figure 1. Similar to the results of
the Jurkat-Jurkat cell assay, all four anti-CD4 binding site
bNabs were able to block HIV-1 cell-cell spread from pri-
mary HIV-1 infected T cells to target Jurkat 1G5 T cells
(Figure 3A). Notably, we again found that J3 was the most
potent neutralising antibody tested (IC50 = 0.80 μg/ml),
with HJ16 and VRC01 inhibiting with an IC50 values of
7.55 μg/ml and 8.42 μg/ml respectively (Figure 3C). In this
assay, b12 appeared to be slightly more potent against pri-
mary CD4+ T cell mediated infection (Figure 3A and C)
compared to Jurkat cells (IC50 = 7.13 μg/ml in primary
cells and 16.14 μg/ml in Jurkat cells) but like other CD4-
binding site antibodies it also showed reduced potency
compared to J3. Interestingly, the V1/V2 glycan-specific
antibodies PG9 and PG16 showed increased activity
against the primary CD4+ T cell associated virus during
cell-cell infection (IC50 = 0.60 μg/ml and 0.26 μg/ml).
2G12 on the other hand showed a broadly consistent levelFigure 3 Neutralisation of cell-cell spread by HIV-1 infected primary C
and gp120 glycans (B), and non neutralising antibody controls (B6 and Lab5)
CD4+ T cells for 1 h at 37°C exactly as in Figure 1. Uninfected target T cells co
24 h as described in the methods to allow for cell-cell spread of HIV-1.
virus-only controls and representative of three independent experiments. (C)
of the indicated antibodies in three independent experiments and show theof neutralisation whether the HIV-1 infected cells were
primary or immortalised T cells (Figure 3B). The
MPER-specific bNAb 2F5 was relatively less active against
primary T cell-associated virus, and again 4E10 was inef-
fective at blocking cell-cell spread (Figure 3B).
Efficient neutralisation by J3 is not dependent on
antibody size
It is plausible that the small size of the VHH J3 could be re-
sponsible, at least in part, for the high potency with which
J3 blocked HIV-1 infection relative to the other CD4-
binding site antibodies we tested. However, when the
IC50 values for inhibition of cell-cell spread mediated
by primary CD4+ T cells were compared on a molar
scale we found that J3 remained the most potent of the
anti-CD4 binding site antibodies tested (IC50 J3 =
0.055 μM +/−0.018; HJ16 = 0.104 μM +/− 0.036; VRC01 =
0.116 μM +/−0.036; b12 = 0.098 μM +/−0.038), with only
PG9 and PG16 showing similar or better activity (PG9 =D4+ T cells. Antibodies targeting the CD4 binding site (A), the MPER
, were serially diluted and incubated with HIV-1 (NL4.3) infected primary
ntaining a luciferase-reporter gene were added and cells incubated for
Data are shown as the percentage neutralisation normalised to
The average IC50 values (μg/ml) were generated from duplicate titrations
mean with the SEM.
McCoy et al. Retrovirology 2014, 11:83 Page 6 of 15
http://www.retrovirology.com/content/11/1/830.037 μM +/−0.013; PG16 = 0.0069 μM +/−0.002). To dir-
ectly consider the impact of size on neutralisation by J3, J3
VHH DNA was cloned upstream of a human immuno-
globulin (IgG) CH2-CH3 region (J3-Fc), expressed in HEK
293 cells and purified by affinity to protein A. This process
allowed reconstruction of J3 into the original heavy chain
only format in which it was elicited in response to immun-
isation [22] but with a human Fc region. First we assessed
cell-free neutralisation by J3 and J3-Fc against a panel of vi-
ruses that were either sensitive or resistant to neutralisationFigure 4 Enhanced potency of full-length HCAb antibodies. (A) IC50μM
the viruses listed. Very potent neutralisation (<0.001) is indicated in dark gr
in light grey (0.01-0.5) and weak neutralisation in white (>0.5). IC50 values w
cells as described in the methods. (B) Fold increase in IC50 for J3-Fc relativ
is indicated on the X axis.by the VHH J3 monomer in the TZM-bl assay (Figure 4A).
In all cases where monomeric VHH J3 neutralised a viral
strain, the IC50 (μM) of the VHH-Fc was more potent than
that for the individual VHH. However, where the mono-
meric J3 was unable to neutralise a particular strain, the
corresponding J3-Fc was also unable to neutralise. For ex-
ample, Du172.17 is resistant to both J3 and J3-Fc. Notably,
for all but one strain, the J3-Fc was more potent than the J3
monomer resulting in a decrease in IC50 of between two-
and eleven-fold for thirteen out of fourteen viruses testedfor the mono-specific bivalent J3-Fc in comparison to J3 alone for
ey; potent neutralisation (0.001-0.01) in grey, intermediate neutralisation
ere generated from duplicate titrations of J3 and J3-Fc onto TZM-bl
e to J3 for indicated viruses. The subtype/CRF of each individual virus
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variety of HIV-1 strains across a range of clades and tiers,
generally with enhanced potency, strongly suggests that the
immunisation-elicited parental HcAbs from which J3 was
derived would have similar potent neutralisation ability,
and negates the hypothesis that these VHH neutralise HIV
effectively due to their smaller size.
Next we compared J3 VHH (14.5 kDa) and J3-Fc
(82 kDa) for inhibition of cell-cell spread. Figure 5A shows
that both J3 and J3-Fc potently neutralised the cell-cell
spread of HIV-1 with IC50 values of 0.136 μM and
0.040 μM respectively. The increased potency of J3-Fc,
when considered on a molar scale, is highly statisticallyFigure 5 Antibody size is not a limit to neutralisation of cell-cell spre
the J3 VHH and full length heavy chain only J3 (J3-Fc) incubated for 1 h w
luciferase-encoding cells for 24 h as for Figure 1. Student’s t-test was perfo
cell-cell spread when J3 was added during (t = 0 h) or after (t = 1 h and t =
Statistical analysis was performed using a student’s t- test. (C) Immunofluor
access the virological synapse formed during cell-cell contact between a G
(red), J3 (green) and DAPI (blue). Scale bar is 5 microns. (D) Inhibition of vir
cells were mixed with uninfected T cells in the presence of J3, J3-Fc or con
permeabilised, stained for HIV-1 Gag and imaged by immunofluorescence
formed between HIV-1 infected T cells and uninfected target T cells (define
are the mean and SEM from 3 independent experiments. Statistical analysis
Tukey’s post-test.significant (p = 0.0006) and is consistent with data ob-
tained when evaluating J3-Fc neutralisation of cell-free
infection against multiple viruses (Figure 4). Thus we
conclude that efficient neutralisation of cell-cell spread
by J3 when compared to other antibodies is not simply
due to its smaller size.
J3 inhibits virological synapse formation
The predominant mode of HIV-1 cell-cell spread is across
virus-induced virological synapses [5,40] that form at sites
of physical cell-cell contact. It has previously been shown
that virological synapses are dynamic contacts with a
mean contact time of 62 min and that antibody targetingad by J3. (A) IC50 values (μM) generated from duplicate titrations of
ith HIV-1 (NL4.3) infected Jurkat cells and then mixed with target 1G5
rmed using data from 3 independent experiments. (B) The percentage
3 h) mixing HIV-1 infected Jurkat cells and uninfected 1G5 target cells.
escence staining showing J3 (top panel) and J3-Fc (bottom panel) can
ag + HIV-1 infected T cell and an uninfected target T cell (asterisk). Gag
ological synapse formation by J3 and J3-Fc. HIV-1 (NL4.3) infected T
trol (Lab5) and incubated for 1 h at 37°C. Cells were then fixed and
microscopy. Random fields were selected and the number of synapses
d by polarisation of Gag to the cell-cell interface) were scored. Data
was performed by comparing to control Lab5 using an Anova with
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added up to 3 h after mixing infected and uninfected cells
[10]. To determine whether J3 can also neutralise cell-cell
spread after synapse formation, we added the antibody at
the time of mixing infected and uninfected cells (t = 0 h)
or 1 h and 3 h post-mixing. Strikingly, the percentage neu-
tralisation mediated by 10 μg/ml of J3 was maintained
whether the antibody was added during (t = 0) or after
mixing (t = 1 h and t = 3 h) (Figure 5B), similar to previous
reports with human IgG [10].
The HIV-1 T cell virological synapse is defined by en-
richment of HIV-1 Gag and Env at sites of cell-cell contact
and is dependent on receptor-mediated intercellular inter-
actions. Indeed, studies have shown that antibodies against
HIV-1 Env that target the CD4 binding site can access the
cell-cell interface and inhibit synapse formation [5,9,12].
Therefore, having shown that both J3 and J3-Fc can block
cell-cell spread we next investigated whether these anti-
bodies inhibit synapse formation. Immunofluorescence
microscopy staining revealed that both J3 and J3-Fc could
be detected at intercellular junctions formed between
HIV-1 infected and uninfected T cells, engage HIV-1 Env
and stain the cell-cell interface (Figure 5C). Quantification
of synapse formation revealed that both J3 and J3-Fc sig-
nificantly decreased the percentage of virological synapses
that formed between HIV-1 infected and uninfected T
cells by 65% and 85% respectively (Figure 5D).Figure 6 Neutralisation of cell-cell spread between autologous prima
gp120 glycans were serially diluted and incubated with HIV-1 (NL4.3) infect
Dye-labeled uninfected autologous primary target T cells were added and
were then fixed and stained for intracellular HIV-1 Gag and analysed by flo
Gag + target cells in the absence of antibody (untreated) or in the presenc
(50 μg/ml). NI target = uninfected target cells only. (B) The percentage of G
quantified and IC50 values (μg/ml) were calculated. A representative fromNeutralisation of cell-cell spread between primary T cells
Inconsistencies exist in the literature about the relative ef-
ficacy of bNabs during cell-cell spread between primary T
cells. Therefore we next tested our panel of bNabs for in-
hibition of primary T cell-primary T cell spread using an
established flow cytometry Gag transfer assay [14,41]. To
do this CD4+ T cells were isolated from peripheral blood
mononuclear cells, stimulated with PHA and IL-2 and in-
fected with HIV-1 by spinoculation. After 48 h, HIV-1 in-
fected primary CD4+ T cells were incubated with serial
dilutions of antibodies and mixed with autologous, dye la-
beled primary CD4+ T cells and cell-cell spread quantified
by flow cytometry to measure the percentage of Gag + tar-
get cells in the presence of various concentrations of
bNabs. Figure 6 shows that again J3 and J3-Fc were the
most inhibitory CD4 binding site antibodies tested (IC50
μg/ml = 1.5 and 1.8 respectively), with VRC01 inhibiting
with an IC50 of 6.5 μg/ml, b12 of 19.3 μg/ml and some-
what surprisingly HJ16 showing reduced efficacy with an
IC50 of 41.9 μg/ml. Similar to what we found with
primary-Jurkat inhibition, PG9 and PG16 were effective
inhibitors of cell-cell spread mediated by primary CD4 T
cells (IC50 of 1.5 μg/ml and 0.4 μg/ml respectively)
whereas MPER antibodies 2F5 and 4E10 were again poor
inhibitors (IC50 of 41.7 μg/ml and >50 μg/ml respect-
ively), while 2G12 also failed to block at the highest con-
centration tested.ry T cells. Antibodies targeting the CD4 binding site, the MPER and
ed primary CD4+ T cells for 1 h at 37°C exactly as in Figure 1.
cells incubated for 48 h to allow for cell-cell spread of HIV-1. T cells
w cytometry. (A) Representative dot plots showing the percentage of
e of 5 μg/ml J3, J3-Fc or VRC01. 4E10 did not inhibit cell-cell transfer
ag+, dye-labeled target T cells relative to untreated controls was
experiments performed with two independent donors is shown.
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phages to T cells
Cell-cell spread of HIV-1 is not restricted to dissemination
of virus between T cells. Macrophages can also transmit
virus by direct cell-cell spread to T cells [12,42]. Macro-
phages support productive infection by HIV-1 and are also
considered to act as long-lived reservoirs that may contrib-
ute to viral persistence. We therefore assessed the ability of
VHH J3 and J3-Fc to block cell-cell spread of HIV-1 from
macrophages to primary T cells. Monocytes were purified
from whole blood, differentiated into macrophages in vitro,
infected with the macrophage-tropic HIV-1 BaL strain and
co-cultured with autologous CD4+ T cells in the presence
of different concentrations of J3, J3-Fc or the non-
inhibitory controls Lab5 and B6. CD4+ T cells were sepa-
rated from macrophages after 48 h and the proportion of
Gag + T cells was quantified by flow cytometry. Figure 7
shows that the percentage of T cells which stained positive
for HIV-1 Gag was significantly lower in the presence of J3
compared to the control (Lab5) at both 10 μg/ml (p =
<0.0001) and 1 μg/ml (p = <0.0001). Furthermore, J3-Fc
also significantly reduced spread of HIV-1 from macro-
phages to T cells at both 10 μg/ml (p = 0.02) and 1 μg/ml
(p = 0.003). Taken together, these data show that J3 and
J3-Fc potently neutralise cell-cell spread of HIV-1 between
relevant human cell types including CD4+ T lymphocytes
and macrophages and that that size does not appear to
preclude antibody from inhibiting of macrophage-T cell
spread when the antibody targets the CD4 binding site.Figure 7 Neutralisation of cell-cell spread from macrophages to
T cells by J3 and J3-Fc. HIV-1 (BaL) infected macrophages were
incubated with the indicated concentrations of (A) J3, (B) J3-Fc
and negative controls (Lab5 or B6) for 1 h at 37°C. An equal
number of autologous, uninfected CD4+ T cells were then added and
cells incubated for 48 h. T cells were recovered from macrophages by
washing, fixed and stained for intracellular HIV-1 Gag and analysed
by flow cytometry. The percentage of Gag + T cells relative to controls
(Lab5 for J3 and B6 for J3-Fc) is shown. Data are the mean and SEM
from 3 independent experiments. Statistical analysis was performed by
Anova with Tukey’s post-test.Discussion
Since 2009 the discovery of the new generation of anti-
HIV-1 bNabs has re-invigorated attempts to elicit protect-
ive antibodies via vaccination [3] with recent advances
culminating in the development of cleaved trimeric Env
that binds exclusively to bNabs [43]. In parallel, it has
been shown that cell-cell HIV-1 spread is resistant to
some anti-retrovirals [16,17] so it has been hypothesised
that this mode of infection could be involved in the per-
sistence of viral reservoirs in patients on therapy. Further-
more, it has been suggested that cell-cell spread of HIV-1
could be resistant to neutralising antibodies due to more
temporal and/or spatial constraints imposed on the anti-
bodies between two cells, as opposed to between a cell
and budded HIV-1 virion. However, the bNab b12 has
been visualised at the virological synapse [10], thus weak-
ening the size restriction argument, although it remains
plausible that the higher efficiency of cell-cell spread
could render certain bNabs ineffective. Therefore ef-
forts are underway to assess the effectiveness of bNabs
during cell-cell spread and to identify antibodies cap-
able of most effectively blocking this mode of HIV-1
spread [10,18,44,45].In this study we have evaluated a panel of bNabs for
their inhibitory activity during cell-cell spread including
a number of second generation antibodies that have not
been previously evaluated for inhibition of cell-cell spread
of HIV-1 (J3, HJ16 and PG9). Of this group, we find that
J3, a highly broadly neutralising llama antibody induced
by immunisation that targets the CD4 binding site can po-
tently neutralise cell-cell HIV-1 spread between physiolo-
gically relevant human cell types including T cells and
macrophages. Furthermore this effect is not simply due to
the smaller size of the VHH since J3-Fc displayed in-
creased neutralisation of both cell-free and cell-cell
spread. Different assays for cell-cell spread may necessitate
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comparison of IC50s complicated; however, we have con-
sistently found that while bNabs VRC01, HJ16, PG9,
PG16, b12, 2G12 and 2F5 are all capable of inhibiting T
cell-T cell HIV-1 spread to varying degrees, 4E10 is not.
Importantly, directly comparing antibodies for inhibition
of cell-cell spread between primary T cells yielded similar
results and we consistently found that antibodies targeting
the MPER were poor inhibitors of T cell-T cell spread me-
diated by primary T cells.
J3 is a highly potent inhibitor of HIV-1 and has been
shown to recognise up to 96% of viral circulating strains
and neutralise cell-free virus with a median IC50 of
0.9 μg/ml [22]. That J3 can also inhibit T cell-T cell and
macrophage-T cell spread of HIV-1 at low concentrations
(1 μg/ml) supports the development of J3 as a prophylac-
tic agent against HIV-1. Indeed the thermal and pH stabil-
ity of VHH [26] coupled with the breadth and potency of
J3 makes it potentially useful as part of a microbicide gel,
and a study is underway to assess the efficacy of a J3-gel
in a non-human primate high dose challenge. By reconsti-
tuting the heavy-chain only J3 into an antibody format to
produce J3-Fc, we demonstrated here that inhibition of
cell-cell infection by J3 was not simply a product of its
smaller size since J3-Fc is six times larger than J3 but was
consistently better able to neutralise cell-associated and
cell-free virus infection. Previous studies have shown bi-
valent VHH have increased affinity for antigen and po-
tency of neutralisation [46,47]. This increase in potency is
therefore likely due to avidity effects conferred by the bi-
valent nature of J3-Fc since the J3 HCAb was more po-
tently neutralising of cell-free virus when compared to the
VHH alone on a molar scale against eleven viruses from
subtypes A, B, C and CRF AG and BC including transmit-
ter/founder viruses. Thus the high affinity and resulting
neutralisation potency and breadth of J3 does not result
from it being smaller versions of the naturally occurring
antibodies, as was the case for the Fab fragment of the hu-
man mAb 17b [48].
That llama-human hybrid VHH-Fc molecules are more
potently neutralising and contain human Fc receptors en-
abling antibody effector functions is encouraging when
considering their potential application as reagents for HIV
prophylaxis mediated by passive transfer of neutralising
antibodies [49]. A further useful comparison would have
been with a conventional heavy and light chain J3 anti-
body; however, it is not possible to construct such a
chimera as the VHH framework 1 signature prevents light
chain interaction and altering this region would allosteri-
cally disrupt the J3-Env interface. However, our finding
that the conventional patient-derived antibody HJ16 can
neutralise cell-cell infection mediated by Jurkat T cells
with comparable potency to J3 indicates that the add-
itional width of a double-headed immunoglobulin is notdisadvantageous in blocking cell-cell HIV-1 transmission.
These data are consistent with a previous report that the
Fab fragment of anti-CD4 binding site antibody b12 is less
potent than the full length antibody [50].
The predominant mode of HIV-1 cell-cell spread be-
tween immune cells occurs at virological synapses.
Immunofluorescence imaging has demonstrated that
antibodies are readily able to access antigen at the HIV-
1 virological synapse [5,6,9,10,12,13], disrupt synapse
formation and reduce cell-cell spread. That the llama
antibody VHH J3 and the reconstituted heavy-chain
format J3-Fc can be detected at intercellular contacts
formed between HIV-1 infected and uninfected T cells,
and can significantly inhibit synapse formation, sug-
gests that inhibition of cell-cell spread by J3 and J3-Fc
may be mediated, at least in part, by their ability to
interfere with Env-CD4 binding and impair virological
synapse formation, as well as by direct neutralisation of
virus during transmission across the synapse.
J3, VRC01, HJ16 and b12 all target the CD4 binding
site on Env, which has been suggested to be more re-
sistant in TZMbl cells to an antibody-mediated block-
ade of cell-associated virus relative to cell-free virus
[18]. Comparing antibody potency between two differ-
ent modes of infection is complicated when the effi-
ciency of transmission varies as greatly as in the case of
cell-cell and cell-free spread of HIV-1 [51]. Inherently,
cell-cell transmission is more efficient and thus infec-
tious units of virus are greater and pose a larger obs-
tacle to any inhibitor. However, by directly comparing
the relative potencies of different antibodies targeting
the same site on HIV-1, we can also consider whether
any particular site, such as the CD4 binding site, is less
exposed during cell-cell spread and thus whether the
groups of bNabs vary in their ability to block the same
viral strain based on the mode of infection. If a specific
site is less effectively targeted or less accessible to anti-
body during cell-cell transmission then no antibodies
targeting that site should be capable of potent inhib-
ition of this mode of infection. However, this is not
what we observed for CD4 binding site antibodies dur-
ing cell-cell spread. Here we found that J3 and (under
most conditions) HJ16 efficiently blocked cell-cell
spread of HIV-1, while VRC01 and b12 showed variable
efficacy. Consistent with our results, VRC01 and b12
were reported to be relatively weak inhibitors of cell-
cell spread in other studies [10,18,44,45]. The particu-
larly weak activity of b12 may reflect variation in the
binding kinetics of the different antibodies, or differ-
ences in how the boundaries of the CD4 binding site
are defined; since CD4 binding site antibodies are
grouped primarily for their ability to compete with sol-
uble CD4 for binding to Env and inability to bind Env
point mutants which cannot bind CD4. However, this
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print on Env or contact all of the same viral amino acids.
For example, b12 binds some areas of Env not utilised by
the other antibodies (e.g. VRC01) namely the tryptophan
100 pocket [52] and both b12 and VRC01 can bind a mu-
tant Env that can no longer bind CD4 [23]. Thus CD4
binding site antibodies do not all interact with a single site
on Env, but rather with an overlapping area with different
molecular contacts contributing to each interaction [19].
This may explain why some CD4 binding site mAbs dis-
play potent inhibition of cell-cell spread whilst others do
not.
We found that some antibodies specific for other epi-
topes in Env (glycan moieties, V1/V2 and MPER) were
less efficient in blocking T cell-T cell spread and required
a higher concentration to achieve 50% inhibition of cell-
cell spread compared to antibodies targeting the CD4
binding site. Specifically when compared head to head
across the same concentration range, antibodies targeting
the MPER region (antibodies 2F5 and 4E10) do not per-
form as well as those targeting the CD4 binding site dur-
ing cell-cell spread of this viral strain. This finding is
consistent with recently published data [44]. Therefore
whilst caution should be applied in extrapolating in vitro
data to the in vivo situation to infer that one target may be
a better or worse therapeutic strategy, our data indicate
that some CD4 binding site antibodies can be highly ef-
fective inhibitors of cell to cell spread of HIV-1. Differ-
ences in the inhibitory activity of antibodies targeting
related epitopes also highlights the importance of evaluat-
ing a number of inhibitors targeting the same epitope. It
will also be informative in future to evaluate bNabs during
cell-cell spread using a panel of primary isolates represent-
ing multiple strains and clades to consider whether viruses
that may be more resistant to neutralisation are better able
to exploit cell-cell spread to avoid inhibition.
The relative contribution of cell-free and cell-cell spread
in vivo is difficult to determine. However, cell-to-cell
spread mediated during physical contact between infected
and uninfected cells may be an important mode of HIV-1
dissemination in lymphoid tissues, where CD4+ T lympho-
cytes are densely-packed and likely to frequently interact.
In support of this, recent intravital imaging studies have
validated the concept of the virological synapse in vivo
[53,54]. Because cell-cell spread has been shown to be or-
ders of magnitude more efficient than equivalent cell-free
infection [9-14], it is reasonable to hypothesise that less ef-
ficient antibody-mediated neutralization of cell-cell spread
by some NAbs may impact on viral replication in vivo
[53,54].
It is worth noting that evaluation of bNabs is com-
monly performed using the standardised HeLa TZM-bl
assay in which neutralising activity of antibodies is tested
against different HIV Envs by generating pseudotypedviruses in 293T cells that are then used in cell-free infec-
tion assays. Our data reveal interesting differences in the
ranking of antibodies during cell-free infection using the
TZM-bl assay when compared to cell-cell spread. For ex-
ample J3 was the most potent of the anti-CD4 binding site
antibodies against HIV-1 cell-free infection and main-
tained its ranking as a potent inhibitor when evaluated
against other antibodies during cell-cell infection. By con-
trast, b12 might be predicted to perform well in cell-cell
spread based on the similarity in IC50s values between
b12, VRC01 and HJ16 in cell-free titrations, but this was
not what we found. Other antibodies such as 4E10 per-
formed well in cell-free evaluation against the HIV-1
strain NL4.3 using the standardised TZM-bl assay but
were essentially inactive during cell-cell spread. Thus the
relative potency with which a given antibody will inhibit
cell-cell spread may not necessarily be predicted by its ac-
tivity against cell-free virus when evaluated via the stan-
dardised TZM-bl assay. We propose that valuable insight
could be gained by comparing antibodies targeting the
same site for the ability to inhibit cell-cell infection using
physiologically relevant primary human cells in order to
identify potent inhibitors of cell-cell spread. Since it is well
established that cell-cell infection is a significantly more
efficient mode of virus spread this may pose a more strin-
gent challenge to inhibition, but such endeavours could
help to identify the most effective prophylactic antibodies
for in vivo use to target HIV-1 during the course of nat-
ural infection.
Conclusions
In conclusion, we have tested a panel of bNabs targeting
different sites on Env for their ability to block cell-cell
HIV-1 infection including a number not previously evalu-
ated for inhibition of cell-cell spread. We identify the
VHH J3 as a particularly efficient inhibitor of both cell-
free and cell-cell spread and show that the potency of J3 is
not simply a function of its smaller size, since J3-Fc was
consistently more inhibitory. The ability of J3 and J3-Fc to
inhibit cell-cell spread of HIV-1 between T cells and from
macrophages to T cells at concentrations within the
low μg/ml range, coupled with the thermal and pH stabil-
ity of VHH, provides strong support for the development
of J3 as a novel therapeutic with studies underway to as-




The following HIV-1 molecular clones or viruses were ori-
ginally obtained from the NIH AIDS Reagent and Refer-
ence Program (ARRP, NIH, USA): HIV-1 molecular clone
pNL4.3 produced by M. Martin; BaL virus donated by S.
Gartner, M. Popovic and R. Gallo; transmitter/founder
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http://www.retrovirology.com/content/11/1/83virus clones CH058 and CH077 obtained from Dr. John
Kappes and Dr. Christina Ochsenbauer [55,56]; and the
subtype B and C HIV-1 Reference Panels of Env Clones
[57,58]. The 96ZM651.02 gp160 clone was kindly pro-
vided by Dr D. Montefiori (Duke University Medical
Center, Durham, NC) through the Comprehensive Anti-
body Vaccine Immune Monitoring Consortium (CA2
VIMC) as part of the Collaboration for AIDS Vaccine
Discovery (CAVD). Virus was prepared from molecular
clones by transfection of 293T cells and virus titrated
on HeLa-TZM-bl reporter cells using the Bright-Glo
Luciferase assay kit (Promega) to calculate the viral titer
(TCID50/ml). HIV-1 envelope pseudotyped viruses were
produced in 293T cells by co-transfection with the
pSG3Δenv plasmid and virus titrated on HeLa-TZM-bl
reporter cells as above. BaL virus was prepared by passage
in human peripheral blood mononuclear cells and was a
gift from P. Mlcochova. All cell-cell transmission experi-
ments were performed using the HIV-1 strain NL4.3
except for macrophage - T cell transmission assays that
were performed using HIV-1 BaL.Cells
HeLa-TZM-bl cells were obtained from the Centre for
AIDS Reagents, National Institutes of Biological Stand-
ard and Control, UK (CFAR, NIBSC) and donated by J.
Kappes, X. Wu and Tranzyme Inc. and cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) supple-
mented with streptomycin (100 μg/ml), penicillin (100
U/ml) and 10% fetal calf serum (FCS, Invitrogen). The
CD4+/CXCR4+ T cell line Jurkat CE6.1 and derivative
Jurkat line 1G5 (obtained through the ARRP NIH: from
Dr. Estuardo Aguilar-Cordova and Dr. John Belmont)
were maintained in RPMI 1640 supplemented with
streptomycin (100 μg/ml), penicillin (100 U/ml) and 10%
fetal calf serum (Invitrogen). Primary CD4+ T cells were
isolated from peripheral blood mononuclear cells by
Ficoll-Hypaque gradient, stimulated with 1 μg/ml PHA
(Sigma) and 10 IU/ml IL-2 (CFAR, NIBSC, UK) and
CD4+ T cells isolated by negative selection according to
manufacturer’s instructions (Miltenyi Biotec). This rou-
tinely gave >90% pure CD4+ T cells. Primary CD4+ T
cells were maintained in RPMI 1640 supplemented with
streptomycin (100 μg/ml), penicillin (100 U/ml), 20%
fetal calf serum (FCS, Invitrogen) and 10I U/ml IL-2.
Macrophages were purified from peripheral blood
mononuclear cells by Ficoll-Hypaque gradient and
monocytes were allowed to adhere to tissue culture
treaded plates. Non-adherent cells were removed and
autologous CD4+ T cells were purified as described
above. Monocytes were seeded in 48 well trays, differen-
tiated to macrophages with M-CSF and were maintained
in RPMI supplemented with 10% human serum (Sigma).Antibodies
PG9, PG16, b12 and b6 were kind gifts from Dennis Bur-
ton, VRC01 was a kind gift from John Mascola and HJ16
was a kind gift from Davide Corti and Antonio Lanzavec-
chia. 2G12, 2F5, 4E10 were obtained from CFAR NIBSC
and were originally donated by H Katinger (POLYMUN
Scientific GMBH). J3 has been described previously [22].
VHH purification and construction of full-length J3-Fc
HCAB antibody
Expression from the pCAD51 vector incorporates a 6-His
and a c-Myc tag to the C terminus of the VHH and
removes the bacteriophage gene III product. The VHH
were purified by means of the attached His tag using
TALON Metal Affinity Resin (Takara Bio Inc.) as described
previously [22]. DNA encoding J3-Fc was generated using
overlapping PCR with J3 and human immunoglobulin G1
Fc (including the hinge and CH2 and CH3 domains) as
templates. The resulting fragment was ligated into an
expression vector and produced by transient transfec-
tion in HEK 293 cells and purified using Protein A af-
finity chromatography.
TZM-bl neutralisation assay
The neutralising activity of antibodies was assayed in du-
plicate in the TZM-bl cell-based assay against NL4.3 pro-
duced by 293T cells [57,59]. Infection of cells was detected
using with Bright-Glo luciferase reagent (Promega) using
a Glomax plate reader (Promega). IC50 titers were calcu-
lated using the XLFit4 software (IDBS).
T cell-T cell inhibition assay
Jurkat and primary CD4+ T were infected by spinoculating
at 1200 × g for 2 h at an MOI of 0.1-0.2 (calculated using
the TCID50 obtained by titrating virus on TZM-bl cells).
Cells were phenotyped for surface Env expression using
2G12 (POLYMUN) followed by anti-human immuno-
globulin G-phycoerythrin (Jackson Immunoresearch).
Intracellular Gag staining was performed by fixing cells
in 4% formaldehyde, permeabilising in BD Perm/Wash
buffer (Becton Dickinson) and HIV-1 Gag was detected
using the PE-conjugated antibody RC57-RD1 (Coulter).
The percentage of Gag + and Env + cells was quantified
by flow cytometry. To quantify cell-cell spread, 1×104
HIV-1 infected T cells were preincubated with serial di-
lutions of bNAbs and controls for 1 h at 37°C and
mixed with 2.5×105 1G5 Jurkat T cells for 24 h at 37°C.
Cells were then washed and luciferase activity in the
1G5 target cells was measured by luminescence assay
using the Bright-Glo luciferase assay (Promega).
Alternatively, 2×105 HIV-1 infected Jurkat cells were in-
cubated with bNabs for 1 h 37°C and mixed with 1G5
Jurkat T cells in a ratio of 1:4 and at various times
post-mixing the cells were harvested and genomic
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was performed to measure cell-cell spread of HIV-1 as de-
scribed previously [9]. To determine the relative contribu-
tion of cell-cell and cell-free spread to the luciferase signal
in 1G5 target cells over 24 h, HIV-1 infected and unin-
fected cells were incubated as described above (without
bNabs) and the luciferase signal from cell-cell spread was
measured by luminescence. To quantify cell-free infection
in parallel, the same numbers of HIV-1 infected cells were
incubated alone without the addition of target cells for 24 h
in order to allow cell-free virus release. Virus-containing
supernatants were harvested and incubated with 1G5 target
cells for another 24 h to allow cell-free infection and lucif-
erase activity was measured by luminescence.
To measure inhibition of cell-cell spread between au-
tologous primary CD4+ T cells by bNabs a flow cytome-
try Gag transfer assay was used [14,41]. Briefly, CD4+ T
were purified from activated PBMCs as described above
and infected by spinoculation. Forty-eight hours later
5×105 HIV-1 infected primary CD4+ T cells were incu-
bated with bNabs for 1 h 37°C and mixed with 1×106 of
autologous target CD4+ T cells that were prelabeled with
CellTrace Far Red dye. Forty-eight hours later cells were
stained for intracellular HIV-1 Gag as described above
and the percentage of Gag+ dye-labeled target cells was
determined by flow cytometry analysis.
Macrophage-T cell inhibition assay
Quantification of cell-cell spread from macrophages to
T cells was performed essentially as described previously
with minor modifications [12,51]. Briefly, 2 × 105 macro-
phages per well were infected with HIV-1 BaL (30 ng of
p24 per well) for 6 h at 37°C, washed and incubated for
7 days. Macrophages were then incubated with J3, J3-Fc
or a relevant non-specific control (VHH Lab5 for J3 and
B6 for J3-Fc) for 1 h at 37°C after which time 4 × 105 au-
tologous CD4+ T cells (purified and activated with PHA
and IL-2 as described above) were added to each well.
CD4+ T cells were harvested 48 h later by washing,
stained for intracellular HIV-1 Gag as described above
and analysed by flow cytometry.
Immunofluorescence microscopy
HIV-1 infected T cells were washed in RPMI1%-FCS,
mixed with an equal number of uninfected target T cells
and incubated on poly-L-lysine (Sigma) treated coverslips
at 37°C for 1 h in the presence of the VHH J3, J3-Fc or
control antibodies (Lab5 or B6) according to published
methods [5]. The cells were fixed in 4% formaldehyde in
PBS-1% BSA for 15 min, washed and permeabilised in
0.1% Triton X-100/5% FCS and HIV-1 Gag was stained
with rabbit antisera against Gag p17 and p24 (donated by
G. Reid and obtained from the CFAR, NIBSC, UK). Pri-
mary antibodies were detected with anti-rabbit Cy3 (Gag)(Jackson Immunoresearch), anti-human FITC (J3-Fc, B6)
(Jackson Immunoresearch), or mouse anti-Myc antibody
(J3, Lab5) (Millipore) followed by anti-mouse Alexa-488
(Invitrogen). All secondary antibodies were tested for
an absence of inter-species reactivity. Coverslips were
mounted with ProLong antifade mounting solution
(Invitrogen) and imaged using a DeltaVision ELITE Image
Restoration Microscope (Applied Precision/Olympus)
through a 60× 1.4 NA oil immersion lens with an inverted
Olympus IX71 microscope and a CoolSNAP HQ2 camera.
Images were deconvolved with softWoRx 5.0 and process-
ing was performed using Huygens Professional version 4.0
and Adobe Photoshop CS3. Random fields were selected
and the number of contacts between HIV-1 Gag + T cells
and uninfected T cells that had formed virological synap-
ses (defined by polarisation of HIV-1 Gag to the cell-cell
interface) was quantified.
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